<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109533</url>
  </required_header>
  <id_info>
    <org_study_id>3644</org_study_id>
    <nct_id>NCT05109533</nct_id>
  </id_info>
  <brief_title>Probiotics Role in HPV Cervico-vaginal Infection Clearance</brief_title>
  <official_title>Probiotics Role in HPV Clearance When Coexisting Vaginal Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Pisana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaginal infections demonstrated to be implicated in the persistence of HPV, activating a&#xD;
      vicious circle of vaginal microbial perturbations. HPV infection can destroy the biofilm&#xD;
      barrier formed by the local vaginal immune microenvironment, leading to a condition called&#xD;
      dysbiosis. Contemporarily, the resulting local microecological imbalance in the vagina can&#xD;
      subsequently upregulate the expression of the HPV protein, increasing HPV-related cytological&#xD;
      alterations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 483 women affected by different vaginal infections and concomitant HPV-positivity&#xD;
      were enrolled between 2018 and 2020 at Department of Gynecological, Obstetrical and&#xD;
      Urological Sciences, University &quot;Sapienza&quot; of Rome (Rome, Italy) and 2nd Division of&#xD;
      Obstetrics and Gynecology, Azienda Ospedaliera Universitaria Pisana, University of Pisa&#xD;
      (Pisa, Italy). Women with positive swabs for infections were randomized in two groups,&#xD;
      standard specific treatment (n=231) versus the standard treatment plus long-lasting (9&#xD;
      months) vaginal and oral probiotics implementation (n=252).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of a possible role of probiotics in HPV clearance</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in HPV test positivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation in vaginal infection resolution</measure>
    <time_frame>12 months</time_frame>
    <description>Negative swab test for vaginal infections, complete symptoms resolution, absence of colposcopy findings suggestive for permanence of infections (e.g. colpitis, fine punctuation, etc), absence of infection following Amsel's criteria</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">483</enrollment>
  <condition>Vaginal Infection</condition>
  <condition>HPV Infection</condition>
  <arm_group>
    <arm_group_label>Group 1 - ARM WITH STANDARD TREATMENT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard specific treatment for vaginal infections following latest version of CDC guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - ARM WITH STANDARD TREATMENT PLUS PROBIOTICS IMPLEMENTATION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard specific treatment for vaginal infections plus long-lasting (9 months) vaginal and oral probiotics implementation (Lactobacillus rhamnosus BMX 54 vaginally and Lactobacillus reuteri RC-14/Lactobaciullus rhamnosus GR-1 combination orally)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactobacillus rhamnosus BMX 54, Lactobacillus reuteri RC-14, Lactobacillus rhamnosus GR-1</intervention_name>
    <description>Probiotics implementation</description>
    <arm_group_label>Group 2 - ARM WITH STANDARD TREATMENT PLUS PROBIOTICS IMPLEMENTATION</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  positive swabs for vaginal infections detected during colposcopy check&#xD;
&#xD;
          -  HPV test positivity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  concomitant malignancies&#xD;
&#xD;
          -  immunological diseases&#xD;
&#xD;
          -  severe comorbidities&#xD;
&#xD;
          -  prolonged corticosteroid treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Vaginal infection as inclusion criteria</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56120</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Domenici L. Letter to &quot;The application of PAX1 methylation detection and HPV E6/E7 mRNA detection in cervical cancer screening&quot;. J Obstet Gynaecol Res. 2021 Sep;47(9):3419-3420. doi: 10.1111/jog.14912. Epub 2021 Jun 21.</citation>
    <PMID>34155727</PMID>
  </reference>
  <reference>
    <citation>Palma E, Recine N, Domenici L, Giorgini M, Pierangeli A, Panici PB. Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection. BMC Infect Dis. 2018 Jan 5;18(1):13. doi: 10.1186/s12879-017-2938-z.</citation>
    <PMID>29304768</PMID>
  </reference>
  <reference>
    <citation>Recine N, Palma E, Domenici L, Giorgini M, Imperiale L, Sassu C, Musella A, Marchetti C, Muzii L, Benedetti Panici P. Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis. Arch Gynecol Obstet. 2016 Jan;293(1):101-107. doi: 10.1007/s00404-015-3810-2. Epub 2015 Jul 5.</citation>
    <PMID>26142892</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Pisana</investigator_affiliation>
    <investigator_full_name>Lavinia Domenici</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vaginal infections</keyword>
  <keyword>probiotics</keyword>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

